The race is now on for the development of 11-, 13- and even 15-valent glycoconjugate vaccines that could provide even broader protection, target emerging serotypes and be more relevant to the ...

This is a well-known type of vaccine called a glycoconjugate, glycan being another word for describing polysaccharides. For a long time, it was considered impossible to develop a glycoconjugate for E.

In February 2010, a quadrivalent conjugate vaccine (Menveo; Novartis Vaccines and Diagnostics) was approved by the US FDA to prevent invasive meningococcal disease caused by Neisseria meningitidis ...